Table 1 Baseline characteristics of randomized patients with microbiota data available from baseline and study end.
From: Rosuvastatin alters the genetic composition of the human gut microbiome
Placebo | Rosuvastatin | p value | na | |
|---|---|---|---|---|
n = 20 | n = 20 | |||
Age, years | 51.5 (±8.7) | 59.3 (±6.9) | 0.003 | |
Sex (female) | 20 (100) | 20 (100) | 1.000 | |
Current or former smoker | 13 (65) | 13 (65) | 1.000 | |
Body mass index, kg/m2 | 28.3 (±5.1) | 25.2 (±3.8) | 0.052b | |
Hypertension | 4 (20) | 5 (25) | 0.500 | |
Diabetes mellitus type 2 | 0 (0) | 0 (0) | — | |
Family history of CAD | 16 (80) | 13 (65) | 0.240 | |
Medication | ||||
ACEi/ARB | 3 (15) | 1 (5) | 0.302 | |
Beta blockers | 8 (40) | 5 (25) | 0.250 | |
Calcium-channel blocker | 1 (5) | 1 (5) | 0.756 | |
Aspirin | 14 (70) | 13 (65) | 0.500 | |
Proton pump inhibitors | 3 (15) | 0 (0) | 0.115 | |
Biochemistry | ||||
Total cholesterol, mmol/L | 6.0 (±1.5) | 5.9 (±1.0) | 0.923 | |
LDL, mmol/L | 4.0 (±1.4) | 3.7 (±0.9) | 0.422 | |
HDL, mmol/L | 1.5 (±0.6) | 1.9 (±0.4) | 0.035 | |
Triglycerides, mmol/L | 1.8 (±0.9) | 1.3 (±0.6) | 0.038 | |
Hemoglobin, g/dL | 14.1 (±0.7) | 13.9 (±0.8) | 0.485 | |
Creatinine, µmol/L | 65.5 (±11.4) | 64.6 (±7.0) | 0.765 | |
Total bilirubin, mg/dL | 6.3 (±2.4) | 7.5 (±5.0) | 0.362 | 18/19 |
AST, U/L | 22.4 (±6.7) | 25.5 (±5.9) | 0.134 | |
ALT, U/L | 21.1 (±11.3) | 22.4 (±7.5) | 0.674 | 19/20 |
ALP, U/L | 65.6 (±18.5) | 62.0 (11.7) | 0.481 | 17/19 |
HbA1c, % | 5.7 (±0.4) | 5.6 (±0.4) | 0.510 | |
CRP, mg/L | 4.0 (±3.7) | 2.3 (±2.1) | 0.099b | |
